Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013

Before you go, we thought you'd like these...
Before you go close icon

Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYS: TEVA) announced today that it will release its fourth quarter and full year 2012 financial results on Thursday, February 7, 2013 at 7:00 a.m. EST.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EST to discuss its fourth quarter and full year 2012 results and overall business environment. A Question & Answer session will follow this discussion.


In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-771-4371; International 1-847-585-4405; passcode: 34121499.

A live webcast of the call will also be available on Teva's website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until February 14, 2013, at 11:59 p.m. ET by calling 1-888-843-7419 or 1-630-652-3042; passcode: 34121499#.

About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of approximately 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.



Teva
IR:
Kevin C. Mannix, 215-591-8912
United States
or
Joseph Marczely, 267-468-4281
United States
or
Tomer Amitai, 972 (3) 926-7656
Israel
or
PR:
Hadar Vismunski-Weinberg, 972 (3) 926-7687
Israel
or
Denise Bradley, 215-591-8974
United States

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:

The article Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners